Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice

INTRODUCTION: The treatment of choice for Atypical Hemolytic Uremic Syndrome (aHUS) is the monoclonal antibody eculizumab. The objective of this study was to assess the efficacy and safety of eculizumab in a cohort of kidney transplant patients suffering from aHUS. METHODS: Description of the prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: de Andrade, Luis Gustavo Modelli, Contti, Mariana Moraes, Nga, Hong Si, Bravin, Ariane Moyses, Takase, Henrique Mochida, Viero, Rosa Marlene, da Silva, Trycia Nunes, Chagas, Kelem De Nardi, Palma, Lilian Monteiro Pereira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685617/
https://www.ncbi.nlm.nih.gov/pubmed/29136640
http://dx.doi.org/10.1371/journal.pone.0188155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685617/
https://www.ncbi.nlm.nih.gov/pubmed/29136640
http://dx.doi.org/10.1371/journal.pone.0188155

Ejemplares similares